In this article, we will list the 5 Most Promising Stocks Under $100 to Buy. Please visit 15 Most Promising Stocks Under $100 to Buy to see the extended list and the methodology behind it.

5. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelanotide across 4 substudies of rare, genetically driven obesity. The trial did not meet its pre-specified primary endpoints, which measured the difference in mean percent change in BMI (body mass index) compared to a placebo over 52 weeks.

While the primary analysis did not reach statistical significance, post hoc evaluations revealed more encouraging signals in specific patient groups. Significant BMI reductions were observed in patients with heterozygous variants of the POMC/PCSK1 and SRC1 (NCOA1) genes who completed the full 52-week treatment period. These results suggest that while the broader study goals were not met, there is a clear clinical impact for certain genetic profiles, which the company intends to use to inform the development of its next-generation MC4R agonists.

The safety profile of setmelanotide in the EMANATE trial remained consistent with previous clinical experience, with no new safety signals reported. Common side effects included skin hyperpigmentation, nausea, and injection site reactions. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) now plans to use the data from this trial to refine its approach to treating rare neuroendocrine diseases, focusing on its newer drug candidates and exploring additional gene families identified in earlier exploratory research.

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is a healthcare company that focuses on rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide).

4. Stantec Inc. (NYSE:STN)

Stantec Inc. (NYSE:STN) is one of the most promising stocks under $100 to buy. On March 4, Stantec announced that it had been selected to deliver the first phase of Canada’s Arctic Over-the-Horizon Radar (A-OTHR) project, providing critical long-range early-warning coverage for the country’s northern regions. Working under a collaborative integrated project delivery model, Stantec will provide multidisciplinary project management and design services.

The company is part of a consortium where Aecon and Pomerleau will handle construction services as a JV to execute this large-scale defense initiative. The A-OTHR system represents a significant federal investment by the Department of National Defence to modernize NORAD infrastructure. This program aims to establish a sophisticated surveillance network of sensors and command centers capable of detecting aerospace and maritime threats along Arctic routes.

By renewing the North Warning System, the project enhances the ability to monitor and validate potential risks to major North American population centers. This selection builds on Stantec Inc.’s (NYSE:STN) extensive history of providing resilient and climate-ready engineering solutions across Canada. Leadership noted that the partnership reflects decades of collaboration with the Department of National Defence and a shared goal of strengthening critical infrastructure.

Stantec Inc. (NYSE:STN) is an engineering & construction company that offers professional services in the areas of infrastructure to private and public sectors internationally.

3. Marvell Technology Inc. (NASDAQ:MRVL)

Marvell Technology Inc. (NASDAQ:MRVL)  is one of the most promising stocks under $100 to buy. On March 17, Marvell announced the launch of its next-gen Structera S 30260, a 260-lane CXL switch designed to enable rack-level memory pooling in AI data centers. By allowing data center operators to access disaggregated memory resources outside the individual server, the device aims to break through the memory wall that currently limits the performance of LLMs and complex AI clusters.

This new switch works alongside Marvell’s existing portfolio of accelerators and controllers to provide a scalable, composable resource that improves memory utilization without requiring the replacement of existing platforms. The introduction of the Structera S switch follows Marvell Technology Inc.’s (NASDAQ:MRVL) recent acquisition of XConn Technologies, integrating industry-leading switching solutions to facilitate sub-microsecond shared memory access.

This architectural shift is particularly critical for managing the exploding demand for memory capacity driven by increasing context windows and KV-cache requirements in AI inference. By enabling true memory pooling across CPUs, GPUs, and other accelerators, the technology reduces the total cost of ownership while eliminating data movement bottlenecks that typically hinder GPU utilization. The Structera S 30260 is expected to begin sampling to customers in Q3 2026, while the previous generation CXL 2.0 switch is already in production.

Marvell Technology Inc. (NASDAQ:MRVL) is an international tech company that offers data infrastructure semiconductor solutions, spanning the data center core to the network edge.

2. Itron Inc. (NASDAQ:ITRI)

Itron Inc. (NASDAQ:ITRI) is one of the most promising stocks under $100 to buy. On March 16, Itron announced that it is expanding its AI-powered distributed intelligence capabilities through a collaboration with Nvidia (NASDAQ:NVDA) to modernize electric grid management. The companies recently showed the integration of Itron’s grid edge intelligence applications with the Nvidia Jetson platform. This integration allows for real-time data analysis directly from Itron endpoints, strengthening the ability of utilities to manage complex energy and water infrastructure with greater precision.

The collaboration focuses on harnessing high-performance compute to process waveform data at the grid edge for local anomaly detection. By deploying AI locally, the system can identify systemic risks such as electrical faults or wildfire threats much faster than traditional centralized methods. This approach enables continuous learning, allowing the infrastructure to recognize and predict hazardous conditions, which reduces risks to people and property while improving situational awareness for utility providers.

As grid topology grows increasingly complex, this partnership addresses the urgent need for low-latency processing of high-fidelity data closer to the source. Itron’s distributed intelligence portfolio, supported by Nvidia’s high-performance hardware, allows for AI-assisted analytics at scale across the entire distribution grid. This shift toward edge-based inference ensures that utilities can make faster, more informed decisions to maintain the resiliency, reliability, and affordability of the modern power grid.

Itron Inc. (NASDAQ:ITRI) offers end-to-end tech solutions to manage energy, water, and smart city operations. The company operates through the Device Solutions, Networked Solutions, Outcomes, and Resiliency Solutions segments.

1. Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)  is one of the most promising stocks under $100 to buy. On March 16, Mirum Pharmaceuticals announced the completion of enrollment for its Phase 3 EXPAND study, which evaluates the efficacy and safety of LIVMARLI (maralixibat) in treating cholestatic pruritus. This randomized, double-blind, placebo-controlled trial focuses on patients aged 6 months and older who suffer from rare cholestatic liver diseases, such as biliary atresia.

The company aims to use this study to support a potential label expansion, addressing the debilitating itch and limited treatment options currently available for these specific conditions. The study specifically targets the impaired bile flow and elevated serum bile acids that lead to severe pruritus and a significantly reduced quality of life for affected families.

LIVMARLI is currently approved in the US and EU for pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis, but the EXPAND study represents a critical milestone in reaching a broader patient population. Leadership from Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and experts in pediatric medicine emphasized that for many of these rare conditions, there are still no approved targeted therapies for relentless itching. Topline data from the study is expected to be released in Q4 2026.

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is a biotech company that develops and commercializes novel therapies for rare & orphan diseases. The company’s lead product candidate, LIVMARLI (maralixibat), treats cholestatic pruritus in patients with Alagille syndrome.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.